Multiple chemical sensitivity
Authors:
D. Hrubá; A. Peřina
Authors place of work:
Ústav ochrany a podpory zdraví
; Přednostka: prof. MUDr. Zuzana Derflerová Brázdová, DrSc.
; Lékařská fakulta Masarykovy Univerzity, Brno
Published in the journal:
Prakt. Lék. 2017; 97(1): 3-8
Category:
Reviews
Summary
The term multiple chemical sensitivity (MCS) has been adopted for the description of individual’s multi-organ sensitivities following exposures to very low levels of chemicals commonly tolerated by majority of people. People with MCS obviously response to odours by acute respiratory distress, palpitations, skin eruptions and other physical symptoms. The spectrum of chemical triggers becomes wider over time; the reactions become more severe and long lasting. A large number of toxicological, immunological, psychological and neurological mechanisms have been suggested, but none of them could clearly explain the basis of MCS. It is also discussed a possibility of some genetic predisposition. It is estimated that about 9–33% of the population can show the MCS responses, about 2% of them ask physicians for the help. MCS can seriously disrupt the quality of life.
Unfortunately, this uncertainty about aetiology and pathogenesis of MCS is attended with the absence of effective treatment. The clinical approach advices to adopt chemical-free, isolated lifestyle, which can minimize continual exposure. The neuro-behavioural approach is oriented on the stress coping, even with the support of anti-depressive drugs. The recent recommendation is the multidisciplinary approach (general practitioners, immunologists, allergists, gynaecologists, dentists, neurologists, psychologists) after controlling and excluding of possible somatic or psychiatric disease.
Keywords:
multiple chemical sensitivity – low-levels exposure – mechanisms – treatment
Zdroje
1. Alessandrini M, Micarelli A, Bruno E, et al. Intranasal administration of hyaluronan as a further resource in olfactory performance in multiple chemical sensitivity syndrome. Int J Immunopathol Pharmacol 2013; 26: 1009–1015.
2. Bailer J, Witthoff M, Bayerl C, Rist F. Syndrome stability and psychological predictors of symptom severity in idiopathic environmental intolerance and somatoform disorders. Psychol Med 2007; 37: 271–281.
3. Baines CJ, McKeown-Eyssen GE, Riley N, et al. Case-control study of multiple chemical sensitivity, comparing haematology, biochemistry, vitamins and serum volatile organic compound measures. Occup Med 2004; 54: 408–418.
4. Bell IR, Szarek MJ, Dicensor DR, et al. Patterns of waking EEG special power in chemical intolerant individuals during repeated chemical exposures. Int J Neurosci 1999; 97: 41–59.
5. Bell JR, Schwartz GE, Baldwin CM, et al. Individual differences in neural sensitization and the role of context in illness from low-level environmental chemical exposures. Environ Health Persp 1997; 105(Suppl 2): 457–466.
6. Berg ND, Rasmussen HB, Linneber A, et al. Genetic susceptibility factors for multiple chemical sensitivity revised. Int J Hyg Environ Health 2010; 213: 131–139.
7. Black DW, Okiishi C, Schlosser S. A nine-year follow-up of people diagnosed with multiple chemical sensitivities. Psychosomatics 2000; 41: 253–261.
8. Bolla KI. Use of neuropsychological testing in idiopathic Environmental intolerance. Occup Med (Lond) 2000; 15: 617–625.
9. Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune systém. Nat Rev Immunol 2012; 12: 180–190.
10. Capuron L, Ravaud A, Miller AH, Dantzer R. Baseline mood and psychological characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy. Brain Behav Immun 2004; 18: 205–213.
11. Clapham DE. TRP channels as cellular sensors. Nature 2003; 426: 517–524.
12. Cooper C. Multiple chemical sensitivity in the clinical setting. Am J Nursing 2007; 107: 66–73.
13. Consensus on Multiple Chemical Sensitivity. Arch Environ Health 1999; 54: 147–149.
14. Cortright DN, Szallasi A. Biochemical pharmacology of the vanilloid receptor TRPV 1: An update. Eur J Biochem 2004; 271: 1814–1819.
15. Dantoft TM, Elbering J, Brix S, Szecsi PB, et al. An elevated pro-inflammatory cytokine profile in multiple chemical sensitivity. Psychoneuroendocrinology 2014; 40: 140–150.
16. Dantzer R. Cytokine, sickness behaviour, and depression. Immunol Allergy Clin N Am 2009; 29: 247–264.
17. Dantzer R, O‘Connor JC, Freund GG, et al. From inflammation to sickness and depression: when the immune systém subjugates the brain. Nat Rev Neurosci 2008; 9: 46–56.
18. Das-Munshi J, Rubin GJ, Wessely S. Multiple chemical sensitivities: review. Curr Opin Otolaryngol Head Neck Surg 2007; 15: 274–280.
19. Davis JM, Calabrese EJ. The biological effect of low level exposures (BELLE). Coments Toxicol 1998; 6: 241–246.
20. Devriese S, Winters W, Stegen K, et al. Generalization of acquired somatic symptoms in response to odours: a pavlovian perspective on multiple chemical sensitivity. Psychomot Med 2000; 62: 751–759.
21. Fiedler N, Kipen HM, DeLuca J, et al. A controlled comparison of multiple chemical sensitivities and chronic fatigue syndrome. Psychosom Med 1996; 58: 38–49.
22. Genuis SJ. Sensitivity-related illness: The escalating pandemic of allergy, food intolerance and chemical sensitivity. Science of the Total Environment 2010; 408: 6047–6061.
23. Gibson PK, Elms ANM, Ruding LA. Perceived treatment efficacy for conventional and alternative therapies reported by people with multiple chemical sensitivity. Environ Health Persp 2003; 111: 1498–1504.
24. Herr CE, Kopka I, Mach J, et al. Interdisciplinary diagnostics in environmental medicine: finding and follow-up in patients with chronic medically unexplained health complaints. Int J Environ Health 2004; 207: 31–44.
25. Hileman B. Multiple chemical sensitivities. Chem and Eng News 1991; 69(20): 26–42.
26. Hrubá D. Syndrom mnohočetné přecitlivělosti na chemické látky. Hygiena 1995; 40(3): 176–179.
27. Hrubá D. Mnohočetná chemická přecitlivělost. Hygiena 2008; 53(4): 144–145.
28. Kadetoff D, Lampa J. Westman M, et al. Evidence of central inflammation in fiblomyalgia-increased cerebrospinal fluid interleukin-8 levels. J Neuroimmunol 2012; 242: 33–38.
29. Kimata H. Effect of exposure to volatile organic compounds on plasma levels of neuropeptides, nervous growth factor and histamine in patients with self-reported multiple chemical sensitivity. Int J Hyg Environ Health 2004; 207: 159–163.
30. Kuzikandathil EV, Wang H, Szabo T, et al. Functional analysis of capsaicin receptor (Vanilloid receptor subtype-1), multimerization and agonist responsiveness using a dominant negative mutation. J Neurosci 2001; 21: 8697–8706.
31. Lee YL, Pai MC, Chen JH, Guo YL. Central neurological abnormalities and multiple chemical sensitivity caused by chronic toluene exposure. Occup Med 2003; 53: 470–482.
32. Maes M, Twisk FN, Kubery M, Ringel K. Evidence for inflammation and activation of cell-mediated immunity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): increased interleukin-1, tumor necrosis factor-alpha, PMN-elastase, lysozyme and neopterin. J Affect Disord 2012; 136: 933–939.
33. Miller CS, Ashford NA. Multiple chemical intolerance and indoor air quality. In Spengler JD, Samet JM, McCarthy JF (Eds.) Indoor Air Quality. Mc Graw-Hill NY2001; 647–665.
34. Miller CS, Prihoda TJ. The Environmental Exposure and Sensitivity Inventory (EESI): a standardized approach for measuring chemical intolerances for Research and Clinical application. Toxicol Ind Health 1999; 15: 370–385.
35. Orriols R, Costa R, Cuberas G, et al. Brain dysfunction in multiple chemical sensitivity. J Neurol Sci 2009; 287: 72–78.
36. Osterberg K, Karlson B, Orbaek P. Personality, mental distress, and risk perception in subjects with multiple chemical sensitivity and toxic encephalopathy. Scand J Psychol 2002; 43: 169–175.
37. Pall ML. Elevated nitric oxide/peroxynitrite theory of multiple chemical sensitivity: central role of N-methyl-D-aspartate receptors in the sensitivity mechanism. Environ Health Persp 2003; 111: 1461–1464.
38. Pall ML. The simple truth about multiple chemical sensitivity. Environ Health Persp 2004; 112: A266–267.
39. Pall ML, Anderson JH. The vanilloid receptor as a putative target of diverse chemicals in multiple chemical sensitivity. Arch Environ Health 2004; 59: 363–375.
40. Pigatto PD, Minoia C, Ronchi A, et al. Allergological and toxicological aspects in a multiple chemical sensitivity cohort. Oxidative Medicine and Cellular Longevity 2013; dostupné na http://dx.doi.org/10.1155/2013/356235
41. Premkumar LS, Ahern GP. Induction of vanilloid receptor channel activity by proteinkinase C. Nature 2000; 408: 985–990.
42. Ross GH. Treatment options in multiple chemical sensitivity. Toxicol Ind Health 1992; 8: 87–94.
43. Saito M, Kumano H, Yoshiuchi K, et al. Symptom profile of multiple chemical sensitivity in actual life. Psychosom Med 2005; 67: 318–325
44. Schwanhaeuser KR. Prevention of bed-blockers and delayed discharge in surgery. In: Prevention of bed-blockers and delay in discharge in surgical wards. Edited by K Schwanhaeuser. Saarbrücken – Germany: LAP LAMBERT Academic Publishing 2010; 89.
45. Skovbjerg S, Brorson S, Rasmussen A, et al. Impact of self-reported multiple chemical sensitivity on everyday life: A qualitative study. Scand J Publ Health 2009; 37: 621–626.
46. Stenn P, Binkley K. Successful outcome in a patient with chemical sensitivity. Treatment with psychological desensitization and selective reuptake inhibitor. Psychosomatics 1998; 30: 547–550.
47. Stone AA, Broderick JE, Shiffman SS, Schwartz JE. Understanding recall of weekly pain from a momentary assessment perspective: absolute agreement between- and within- person consistency, and judged change in weekly pain. Pain 2004; 107: 61–69.
48. Terenesten-Hasseus E, Bende M, Millqvist E. Increased capsaicin cough sensitivity in patients with multiple chemical sensitivity. J Occup Environ Med 2002; 44: 1012–1017.
49. Weaver VM. Medical management of the multiple chemical sensitivity patient. Regul Toxicol Pharmacol 1996; 24: S111–S115.
50. Whistler T, Fletcher MA, Lonergan W, et al. Impaired immune function in Gulf War Illness. BMC Med Genomics 2009; 2: 12–16.
51. Winder Ch. Mechanisms of multiple chemical sensitivity. Toxicology Letters 2002; 128: 85–97.
52. Yunus MB. Central sensitivity syndromes: a new paradigm and group nosology for fibromyalgia and overlapping conditions, and the related issue of disease versus illness. Semin Arthritis Rheum 2008; 37: 339–352.
53. Schwanhaeuser KR. Prevention of bed-blockers and delayed discharge in surgery. In: Prevention of bed-blockers and delay in discharge in surgical wards. Edited by K Schwanhaeuser. Saarbrücken – Germany: LAP LAMBERT Academic Publishing 2010: 89.
Štítky
General practitioner for children and adolescents General practitioner for adultsČlánok vyšiel v časopise
General Practitioner
2017 Číslo 1
- Advances in the Treatment of Myasthenia Gravis on the Horizon
- Memantine Eases Daily Life for Patients and Caregivers
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
- Spasmolytic Effect of Metamizole
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
Najčítanejšie v tomto čísle
- Paracetamol poisoning
- Risk factors of falls in hospitalized patients
- Multiple chemical sensitivity
- Duties of attending physician in assessing the health status for the purposes of disability, social security benefits and employment